European Urology 2008-11-01

Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.

Stéphane Oudard

Index: Eur. Urol. 54(5) , 1094-6, (2008)

Full Text: HTML

Structure	Name/CAS No.	Molecular Formula	Articles
	docetaxel trihydrate CAS:148408-66-6	C₄₃H₅₉NO₁₇
	Docetaxel CAS:114977-28-5	C₄₃H₅₃NO₁₄

Losartan competitively inhibits CYP2C8-dependent paclitaxel ...
2014-01-01
[Biol. Pharm. Bull. 37(9) , 1550-4, (2014)]

The potential of anti-vascular endothelial growth factor the...
2008-05-01
[Eur. J. Cancer 44(7) , 912-20, (2008)]

Advancing bioluminescence imaging technology for the evaluat...
2009-01-01
[Clin. Cancer Res. 15(1) , 238-46, (2009)]

Bevacizumab/docetaxel association is more efficient than doc...
2010-01-01
[Eur. J. Cancer 46 , 3022-36, (2010)]

Novel therapeutic strategies in development for prostate can...
2008-01-01
[Expert Opin. Investig. Drugs 17(1) , 13-22, (2008)]